Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,559,819
  • Shares Outstanding, K 42,742
  • Annual Sales, $ 421,030 K
  • Annual Income, $ -11,020 K
  • 60-Month Beta 1.31
  • Price/Sales 6.12
  • Price/Cash Flow 34.92
  • Price/Book 6.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.39
  • Number of Estimates 7
  • High Estimate 0.49
  • Low Estimate -0.04
  • Prior Year 0.26
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.10 +4.89%
on 09/14/20
64.44 -7.06%
on 08/19/20
-2.36 (-3.79%)
since 08/17/20
3-Month
42.67 +40.36%
on 06/26/20
64.44 -7.06%
on 08/19/20
+15.24 (+34.13%)
since 06/17/20
52-Week
27.46 +118.10%
on 03/23/20
64.44 -7.06%
on 08/19/20
+21.94 (+57.81%)
since 09/17/19

Most Recent Stories

More News
IPG and Pacira BioSciences Announce Collaboration to Reduce Postsurgical Opioid Prescribing and Surgical Procedure Costs

IPG, the industry-leading provider of surgical cost management solutions, and Pacira BioSciences, Inc. (NADSAQ: PCRX), a leading provider of non-opioid pain management options, today announced a collaboration...

PCRX : 59.89 (-0.70%)
Pacira BioSciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference

Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 H.C. Wainwright 22 Annual Global Investment Conference at 3:30 PM ET on Monday, September 14, 2020. Live audio of...

PCRX : 59.89 (-0.70%)
Shares of PCRX Up 74.0% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Pacira Pharmaceu (NASDAQ:PCRX) on April 9th, 2020 at $34.69. In approximately 5 months, Pacira Pharmaceu has returned 73.99% as of today's recent price of $60.35.

PCRX : 59.89 (-0.70%)
Pacira BioSciences Reports Preliminary Net Product Sales of $36.9 Million for August 2020

-- EXPAREL average daily sales at 111% of the prior year for the month of August 2020 --

PCRX : 59.89 (-0.70%)
Pacira (PCRX) Up 4.1% Since Last Earnings Report: Can It Continue?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PCRX : 59.89 (-0.70%)
Uptrend Call Working As Pacira Pharmaceu Stock Rises 79.4% (PCRX)

SmarTrend identified an Uptrend for Pacira Pharmaceu (NASDAQ:PCRX) on April 9th, 2020 at $34.69. In approximately 5 months, Pacira Pharmaceu has returned 79.41% as of today's recent price of $62.23.

PCRX : 59.89 (-0.70%)
Onconova's Cancer Study Fails to Meet Endpoint, Shares Down

Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.

BPTH : 4.25 (+3.41%)
BLRX : 1.7600 (-0.56%)
PCRX : 59.89 (-0.70%)
ONTX : 0.2500 (+2.92%)
Turning Point Therapeutics (TPTX) Looks Good: Stock Adds 5.3% in Session

Turning Point Therapeutics (TPTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

PCRX : 59.89 (-0.70%)
TPTX : 84.01 (+1.34%)
Soleno (SLNO) in Focus: Stock Moves 6.3% Higher

Soleno (SLNO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

PCRX : 59.89 (-0.70%)
SLNO : 1.9900 (+1.53%)
SmarTrend Watching for Potential Pullback in Shares of Pacira Pharmaceu After 1.24% Gain

Pacira Pharmaceu (NASDAQ:PCRX) traded in a range yesterday that spanned from a low of $62.43 to a high of $64.44. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high...

PCRX : 59.89 (-0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade PCRX with:

Business Summary

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc....

See More

Key Turning Points

2nd Resistance Point 61.14
1st Resistance Point 60.52
Last Price 59.89
1st Support Level 59.15
2nd Support Level 58.40

See More

52-Week High 64.44
Last Price 59.89
Fibonacci 61.8% 50.31
Fibonacci 50% 45.95
Fibonacci 38.2% 41.59
52-Week Low 27.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar